Verona Pharma (VRNA)
NASDAQ: VRNA
· Real-Time Price · USD
81.17
3.68 (4.75%)
At close: May 30, 2025, 3:59 PM
81.14
-0.04%
After-hours: May 30, 2025, 05:24 PM EDT
4.75% (1D)
| Bid | 80 |
| Market Cap | 6.9B |
| Revenue (ttm) | 118.53M |
| Net Income (ttm) | -164.02M |
| EPS (ttm) | -2 |
| PE Ratio (ttm) | -40.58 |
| Forward PE | 84.94 |
| Analyst | Strong Buy |
| Ask | 81.9 |
| Volume | 2,825,565 |
| Avg. Volume (20D) | 1,358,606 |
| Open | 78.99 |
| Previous Close | 77.49 |
| Day's Range | 78.12 - 81.73 |
| 52-Week Range | 11.46 - 81.73 |
| Beta | 0.20 |
About VRNA
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol VRNA
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for VRNA stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts1 month ago
+6.38%
Verona Pharma shares are trading higher after the ...
Unlock content with
Pro Subscription
3 months ago
+5.67%
Verona Pharma shares are trading higher after the company reported better-than-expected Q4 financial results.
4 weeks ago · seekingalpha.com
Silencing The Doubters: Verona Pharma Could Be Sitting On A BlockbusterVRNA's COPD drug Ohtuvayre shows impressive Q1'25 net sales of $71.3M in just its third quarter of sales, all but confirming the blockbuster future of the drug. Ongoing R&D and trials, including a pha...
1 month ago · seekingalpha.com
Verona Pharma's Bull Case Holds, But Lifecycle Extension Is CriticalOhtuvayre's robust launch for COPD treatment exceeded expectations, with Q4 revenue of $36.6 million and FY24 revenue of $42.3 million, indicating strong market demand. Verona's financial health is so...